Boston Scientific reveals federal probe of BridgePoint buy, sales
August 7, 2014 by Arezu Sarvestani
Boston Scientific informed investors this week that it’s under investigation by the U.S. Attorney for the District of New Jersey over a cardiology devices company acquired 2 years ago.
Boston Scientific reported in its most recent quarterly report that it was served with a subpoena for information about its 2012 acquisition of BridgePoint Medical as well as sales and training activities for BridgePoint’s CrossBoss CTO-crossing catheter and Stingray CTO re-entry system. Read more
Court defines 'breast implant' in Dow Corning's $2B product liability saga
August 5, 2014 by Arezu Sarvestani
Long-embattled Dow Corning is still on the hook for complaints about 3 of its implantable tissue expanders after a 6th Circuit Court ruled that the devices count as breast implants for the purposes of a liability settlement worth more than $2 billion.
The decision affirms a lower court’s ruling that the mega-settlement was designed to include complaints about Dow tissue expanders that feature silicone envelopes filled with saline to help stretch breast tissue ahead of a permanent implant. Read more
Apex fights to get respiratory masks back in Germany
August 6, 2014 by Arezu Sarvestani
As promised, Apex Medical Corp. appealed an injunction ordered by a German court that kicked its sleep apnea devices out of the country over patent violations.
Arch-rival ResMed won a ruling last month that banned certain Apex devices from the German market, but Apex vowed to rise again. The company appealed the decision in the Regional Court of Munich in Germany and challenged the validity of the Apex’s allegedly infringed patents. Read more
St. Jude and Volcano call a cease-fire
August 8, 2014 by Arezu Sarvestani
Medtech rivals St. Jude Medical and Volcano signed a truce this week to lay down arms in a long-running legal war that involved multiple technologies and subsidiaries on each side.
The companies agreed to settle all existing litigation between them with prejudice and to refrain from filing lawsuits on those technologies for the next 22 years. Neither party paid or received any money or admitted liability as part of the deal. Read more